Marshall Wace LLP Sells 307,404 Shares of Bioventus Inc. (NYSE:BVS)

Marshall Wace LLP trimmed its holdings in shares of Bioventus Inc. (NYSE:BVS - Free Report) by 80.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 73,423 shares of the company's stock after selling 307,404 shares during the quarter. Marshall Wace LLP owned approximately 0.09% of Bioventus worth $771,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in BVS. Plato Investment Management Ltd purchased a new position in shares of Bioventus during the 4th quarter worth $38,000. KLP Kapitalforvaltning AS acquired a new position in Bioventus in the fourth quarter valued at about $75,000. Quantbot Technologies LP purchased a new position in Bioventus during the fourth quarter worth about $103,000. Arizona State Retirement System acquired a new position in shares of Bioventus in the 4th quarter worth approximately $109,000. Finally, HighTower Advisors LLC lifted its stake in Bioventus by 11.3% during the fourth quarter. HighTower Advisors LLC now owns 13,617 shares of the company's stock worth $143,000 after purchasing an additional 1,380 shares in the last quarter. Hedge funds and other institutional investors own 62.94% of the company's stock.

Bioventus Stock Up 5.6 %

NYSE BVS traded up $0.35 on Wednesday, reaching $6.55. The stock had a trading volume of 668,712 shares, compared to its average volume of 453,473. The company has a market capitalization of $536.73 million, a price-to-earnings ratio of -10.74 and a beta of 0.95. The company has a current ratio of 1.41, a quick ratio of 0.99 and a debt-to-equity ratio of 1.85. Bioventus Inc. has a 1 year low of $4.51 and a 1 year high of $14.38. The business has a 50 day moving average price of $8.54 and a 200 day moving average price of $10.18.

Insider Buying and Selling

In related news, SVP Anthony D'adamio sold 4,380 shares of the firm's stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $10.19, for a total value of $44,632.20. Following the completion of the transaction, the senior vice president now directly owns 118,178 shares of the company's stock, valued at approximately $1,204,233.82. This trade represents a 3.57 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Mark Leonard Singleton sold 6,498 shares of the stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $10.19, for a total transaction of $66,214.62. Following the completion of the transaction, the chief financial officer now directly owns 118,817 shares of the company's stock, valued at approximately $1,210,745.23. The trade was a 5.19 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 24,208 shares of company stock valued at $226,138. Company insiders own 32.90% of the company's stock.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the stock. Craig Hallum set a $15.00 price target on shares of Bioventus and gave the stock a "buy" rating in a research note on Wednesday. Canaccord Genuity Group reaffirmed a "buy" rating and set a $15.00 price objective on shares of Bioventus in a research note on Monday, March 17th.

Bioventus Company Profile

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.